Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter issued to California IVF Fertility Center on February 26, 2020, addresses compliance issues related to biologic products used in fertility treatment. Without access to the full letter text or specific subject line details, the precise nature of the violations cannot be determined from the available information. The warning falls under FDA's biologics regulatory authority, which typically oversees products derived from biological sources such as reproductive tissues or cellular materials used in assisted reproductive procedures. Additional details about the specific violations and regulatory requirements involved would require review of the complete Warning Letter document.